Is Omnicell, Inc. (OMCL) Overvalued?
We dive into why Omnicell, Inc. (OMCL) could be considered overvalued on 2026-08-06, based on AAII’s Value Score and Grade.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Commentary & Analysis
Why Omnicell, Inc.’s (OMCL) Stock Is Down 11.41%
As of Thursday, July 30, Omnicell, Inc.’s OMCL share price has dipped by 11.41%, which has investors questioning if this is right time to buy.Jenna Brashear
What You Need to Know About Omnicell, Inc.'s Q3 Earnings
Omnicell, Inc.'s fiscal Q3 earnings report was released on Thursday, July 30. Let's dive in to see if (OMCL) missed or beat analyst's expectations.Michael Rose
Why Omnicell, Inc.’s (OMCL) Stock Is Down 5.32%
As of Tuesday, July 21, Omnicell, Inc.’s OMCL share price has dipped by 5.32%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Which Is a Better Investment, Butterfly Network, Inc. or Omnicell, Inc. Stock?
Learn more about whether Butterfly Network, Inc. or Omnicell, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Financial Summary
| Share Statistics | OMCL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,504.8 | $367.8 | 50% |
|
| Shares Out (Mil) | 46.3 | 40.8 | 45% |
|
| Institutional Ownership | 97.6% | 82.8% | 74% |
|
| Float (Mil) | 44.4 | 35.5 | 44% |
|
| Beta | 0.97 | 0.85 | 58% |
|
| Avg Daily Volume (000s) | 525 | 310 | 57% |
|
| Price Change (52-week) |
4.3% | 65.6% | 55% |
|
| Growth | OMCL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 5.8% | 11.8% | 40% |
|
| Net Income (5yr) | (42.1%) | (5.7%) | 9% |
|
| EPS (5yr) | (44.2%) | 10.2% | 4 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (18.9%) | (15.5%) | 36% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | $0.418 | $2.269 | $2.090 | |
| Month Ago EPS | $0.418 | $2.269 | $2.090 | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $0.469 | $1.938 | $2.195 | |
| Year/Year Chg | (19.6%) | 5,573% | 6,050% | |
| Financials | OMCL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,247 | $119 | 53% |
|
| Net Income (TTM) (Mil) | $39 | ($9) | 53% |
|
| EPS (TTM) | $0.862 | ($0.400) | 59% |
|
| Operating Cash Flow (TTM) (Mil) | $181 | ($3) | 58% |
|
| Net Cash Flow (TTM) (Mil) | ($109) | $1 | 14% |
|
| Long-Term Debt (Q1) (Mil) | $189 | $23 | 49% |
|
| Enterprise Value (Q1) (Mil) | $1,531 | $376 | 46% |
|
| Valuation | OMCL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.16 | 2.72 | 29% |
|
| P/E | 39.2 | 25.7 | 79% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | OMCL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 44.0% | 58.5% | 55% |
|
| Net Margin | 3.1% | (6.9%) | 41% |
|
| ROA | 1.9% | (12.3%) | 54% |
|
| ROE | 3.1% | (11.1%) | 40% |
|
| Liabilities to Assets | 35.4% | 46.6% | 26% |
|
| F-Score | 8 | 4 | 93% |
|
Omnicell, Inc. did not pass any screens on 9/23/2026.
